Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06096844 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 years 2 months later Jan 31, 2035 → Apr 1, 2039
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 330 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Site contacts updated at 1 of 326 sites
  2. Site details revised at 3 of 326 sites
  3. Study sites: 325 to 326
  4. Site details revised at 1 of 325 sites
  5. Site details revised at 2 of 325 sites
Show 5 earlier versionsHide 5 earlier versions
  1. Site details revised at 2 of 325 sites
  2. Study sites: 324 to 325
  3. Site details revised at 1 of 324 sitesv323
  4. Site details revised at 4 of 324 sitesv322
  5. Site details revised at 6 of 324 sitesv321
  1. Primary and study completion pushed from Jan 31, 2035 to Apr 1, 2039 Site details revised at 2 of 324 sitesv320 Show 1 more changeShow less
    • Site details revised at 2 of 324 sites
  2. Primary and study completion dates: Jan 31, 2035 to Apr 1, 2039v319
  3. Study sites: 323 to 324v318
  4. Site details revised at 1 of 323 sitesv317
  5. Study sites: 322 to 323v316
  6. Site details revised at 1 of 322 sitesv315
  7. Site details revised at 1 of 322 sitesv314
  8. Site details revised at 1 of 322 sitesv313
  9. Re-verified, no change to tracked fieldsv312
  10. Site details revised at 2 of 322 sitesv311
  11. Site details revised at 2 of 322 sitesv310
  12. Site details revised at 1 of 322 sitesv309
  13. Trial sites expanded: 319 → 322 locations Site details revised at 1 of 322 sitesv308 Show 1 more changeShow less
    • Site details revised at 1 of 322 sites
  14. Study sites: 319 to 322v307
  15. Site details revised at 1 of 319 sitesv306
  16. Site details revised at 2 of 319 sitesv305
  17. Site details revised at 14 of 319 sitesv304
  18. Site details revised at 1 of 319 sitesv303
  19. Study sites revised (319)v302 See this version in full on ClinicalTrials.gov ↗
  20. Study sites revised (319)v301 See this version in full on ClinicalTrials.gov ↗
  21. Site details revised at 7 of 319 sitesv300
  22. Study sites: 318 to 319v299
  23. Site details revised at 7 of 318 sitesv298
  24. Site details revised at 2 of 318 sitesv297
  25. Site details revised at 1 of 318 sitesv296
  26. Site details revised at 1 of 318 sitesv295
  27. Site details revised at 4 of 318 sitesv294
  28. Site details revised at 5 of 318 sitesv293
  29. Site details revised at 1 of 318 sitesv292
  30. Primary and study completion pushed from Jun 1, 2026 to Jan 31, 2035 Site details revised at 7 of 318 sitesv291 Show 1 more changeShow less
    • Site details revised at 7 of 318 sites
  31. Site details revised at 1 of 318 sitesv290
  32. Study sites: 317 to 318v289
  33. Site details revised at 20 of 317 sitesv288
  34. Site details revised at 1 of 317 sitesv287
  35. Study sites revised (317)v286 See this version in full on ClinicalTrials.gov ↗
  36. Site details revised at 1 of 317 sitesv285
  37. Site details revised at 1 of 317 sitesv284
  38. Study sites: 316 to 317v283
  39. Site details revised at 7 of 316 sitesv282
  40. Study Status, Contacts/Locationsv281
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Trial Details
NCT Number NCT06096844
Lead Sponsor National Cancer Institute (NCI)
Conditions Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Enrollment 304 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov